Abstract 989P
Background
Atezo-Bev is the one of the standard first-line treatments for pts with uHCC. There have been controversies that the efficacy of immune checkpoint inhibitors might be affected by the etiology of HCC. We performed a multinational retrospective study to investigate the impact of disease etiology on the efficacy outcomes with atezo-bev and prognostic factors in real-world uHCC pts treated with first line atezo-bev.
Methods
A total of 161 pts with Child A liver function who received first-line atezo-bev were included in the current analysis from Asan Medical Center (Seoul, Korea), and National Cancer Centre Singapore (Singapore), between July 2016 and July 2022. Pts with Child B liver function or prior systemic therapy were excluded. Tumor response was assessed per RECIST v1.1.
Results
The median age of the pts was 63 years (range, 16-90) and 136 pts (84.5%) were male. The most common etiology was hepatitis B virus (67.0%), followed by non-alcoholic fatty liver disease (NAFLD) (13.0%), alcohol (7.4%) and hepatitis C virus (4.3%). The objective response rate (ORR) of all pts was 23.6%. There was no difference in ORR based on etiology (viral vs non-viral, 22.1% vs 23.1%; NAFLD vs others, 21.1% vs 23.9%). With a median follow-up of 10.9 months(mo) (95% CI, 9.7-13.1), the median progression-free survival (PFS) and overall survival (OS) were 4.1 mo (95% CI, 3.1-6.9) and 14.0 mo (95% CI, 11.2-18.5), respectively. Median PFS and OS did not differ based on etiology (viral vs non-viral; PFS 4.4 vs 4.4 mo and OS, 14.0 vs 13.1 mo; NAFLD vs others; PFS 3.1 vs 4.1 mo and OS, 14.2 vs 14.0 mo). In the multivariable analysis, higher baseline NLR (≥2.5 [median]) was significantly associated with poorer PFS (median 3.8 vs 9.5 mo, HR 2.2, p=0.003) and OS (median 8.8 vs 27.0 mo, HR 5.0, p<0.001) compared to baseline NLR < 2.5. The most common adverse events (any grade) was hypertension (27.3%), followed by thrombocytopenia (16.9%), proteinuria (11.5%), and hemorrhage (11.5%).
Conclusions
Current study showed that disease etiology was not associated with the efficacy outcomes with first line atezo-bev in pts with uHCC, while higher NLR was a significant poor prognostic factor for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.W.M. Tai: Financial Interests, Institutional, Advisory Board: Novartis, celgene, SIRTEX, MSD, BMS, Eisai, Bayer. C. Yoo: Financial Interests, Personal, Invited Speaker: Bayer, Celgene, Eisai, Ipsen, Servier, Roche, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Research Grant: AstraZeneca, Bayer, Servier; Financial Interests, Institutional, Research Grant: Genentech. All other authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18